Scroll to top
Follow Us
–
Fb.
Tw.
Li.
Yt.
Inst.
Skip to content
About
Company
About CLINUVEL
Risk Management & ESG Statement
Mission, Vision & Values
History & Future
People
Board
Management
Corporate Governance
Pharmaceutical Technology
SCENESSE®
About Melanocortins
Published Research
Scientific Communiqués
Pipeline
Disease Entities
Erythropoietic Protoporphyria (EPP)
Variegate Porphyria (VP)
Vitiligo
DNA Repair
Xeroderma Pigmentosum (XP)
Arterial Ischaemic Stroke (AIS)
Healthcare Solutions
Investors
News
Latest News
Share Price
Announcements Calendar
CLINUVEL Online
ASX Announcements
Company Snapshot
Financial Overview
Shareholder Information
Media Coverage
Analyst Coverage
Annual Reports
Enquiries
FAQ
© CLINUVEL PHARMACEUTICALS LTD 2023. All rights reserved. |
Sitemap
|
Disclaimer
|
Privacy Policy
To report
suspected adverse reactions
, contact CLINUVEL via
safety@clinuvel.com
or (US only) the FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch.
Follow Us
–
Fb.
Tw.
Li.
Yt.
Inst.
Contact Us
Search for
Back
2020 Announcements
Newsletter
Kommuniqué IV
Tag
Home
Tag: Kommuniqué IV
Showing 1-1 of 1 results
Categories
2016 Announcements
2017 Announcements
2018 Announcements
2019 Announcements
2020 Announcements
2021 Announcements
2022 Announcements
2023 Announcements
Archive
Clinical
Corporate
Financial
News
Newsletter
Pages
Presentation
Recruitment
Regulatory
Stories
Uncategorized
Filter
Posted by
CLINUVEL
July 23, 2020
2020 Announcements
Newsletter
38 min read
Kommuniqué IV
Liebe Aktionäre, Freunde Es stellt sich eine neue Welt dar, die darauf...
Read More
